CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes
Industry Satellite Symposia
Calendar Export
Future considerations on the horizon for HR+/HER2- EBC
(ID 368)
Lecture Time
19:40 - 19:45
Speakers
S. Tolaney
(Boston, MA, United States of America)
Session Name
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes
Room
Channel 1
Date
Wed, 05.05.2021
Time
19:00 - 20:00